Plasmacytoma is a type of cancer that affects the plasma cells in the bone marrow. It is a rare disease, accounting for less than 1% of all blood cancers. The abnormal proliferation of plasma cells can lead to an overproduction of immunoglobulins, which are proteins produced by the immune system.
Plasmacytoma can be classified into two main types: primary and secondary. Primary plasmacytoma is a solitary tumor that affects only one bone or extramedullary site, whereas secondary plasmacytoma occurs in conjunction with multiple myeloma.
The symptoms of plasmacytoma can vary depending on the location and extent of the disease. Common signs include bone pain, fatigue, weight loss, and recurring infections.
Diagnosis typically involves a combination of physical examination, medical history, and laboratory tests. Imaging studies such as X-rays, CT scans, or MRI may also be necessary to confirm the presence of a tumor.
The treatment approach for plasmacytoma depends on various factors, including the stage and location of the disease. Chemotherapy is often used to reduce the size of the tumor, followed by radiation therapy to eliminate any remaining cancer cells.
In some cases, stem cell transplantation may be necessary to replace the patient's bone marrow with healthy stem cells.